Creating a new kit for making stable, modified RNA efficiently
Official title: Development of a WT RNAP-based kit for high-yield synthesis of chemically modified RNA
Funded at Dotquant, LLC · NIH-11005990 · Data updated 2026-11-12
This study is working on a new kit that makes it easier and cheaper to create special types of RNA, which can be really helpful for things like vaccines and gene therapy, so that more people can benefit from these important medical treatments.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dotquant, LLC NIH-funded |
| Lab location | 1 site (Shoreline, United States) |
| Project start | August 10, 2024 |
| Project end | February 9, 2026 |
| Funding year | 2024 |
| Award (this year) | $305,892 |
| NIH project number | 1R43GM151884-01A1 |
| Project ID | NIH-11005990 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include individuals requiring RNA-based treatments, such as those with genetic disorders or those needing vaccines.
✕Less likely to help
Patients who do not require RNA-based therapies or have conditions unrelated to RNA synthesis may not benefit from this research.
What this research studies
This research focuses on developing a kit that allows for the efficient synthesis of chemically modified RNA, which is crucial for various applications in medicine and biotechnology. The approach combines the high efficiency of wild-type T7 RNA polymerase with the ability to incorporate modified nucleotides, addressing the limitations of current methods. By optimizing the conditions for RNA synthesis, the researchers aim to produce stable RNA that can be used in therapies, vaccines, and genome editing. This could significantly reduce costs and improve the availability of RNA for clinical use.
Why it matters
Potential benefit: If successful, this research could lead to more accessible and effective RNA-based therapies for patients.
How similar studies have gone: Other research has shown promise in developing RNA synthesis techniques, but this specific approach is innovative and aims to overcome existing challenges.
Where this research is happening
-
Dotquant, LLC
Shoreline, United States Active
Researchers
- Principal investigator: Liu, Hong Yan — Dotquant, LLC
- Study coordinator: Liu, Hong Yan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.